Advertisement

Investigational New Drugs

, Volume 36, Issue 4, pp 696–701 | Cite as

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer

  • Motohiro Tamiya
  • Hidekazu Suzuki
  • Takayuki Shiroyama
  • Ayako Tanaka
  • Naoko Morishita
  • Norio Okamoto
  • Kenichi Sakai
  • Hironori Shigeoka
  • Kunimitsu Kawahara
  • Tomonori Hirashima
PHASE III STUDIES
  • 111 Downloads

Summary

Background Bevacizumab (Bev) is generally well-tolerated, and Bev-associated intestinal perforation (BAP) is a rare albeit serious side effect in cases of non-small cell lung cancer (NSCLC). Therefore, the present study aimed to identify clinical predictors of BAP to help predict and manage the development of life-threatening intestinal complications among patients receiving Bev. Methods This retrospective study evaluated demographic, clinical, and treatment factors for patients with NSCLC who were treated with Bev between February 2010 and August 2015 at our center. Results We identified 314 regimens (208 patients; median age: 65 years; 115 women) for analysis, which included 119 first-line regimens, 74 s-line regimens, and 121 third-line or later regimens. BAP occurred in 7 cases (2.23% among all regimens and 3.37% among all patients), which generally occurred during first- or second-line treatment and was caused by ulcerative colitis (1 case), colon diverticulitis (1 case), and idiopathic perforations (5 cases). Univariate analyses revealed that BAP was significantly associated with deteriorating PS during the first cycle of chemotherapy (odd ratio [OR]: 11.07, 95% confidence interval [CI]: 2.37–51.63, p = 0.0022), grade ≥ 3 diarrhea (OR: 11.37, 95% CI: 2.37–54.50, p = 0.0024), febrile neutropenia (OR: 9.16, 95% CI: 1.98–42.49, p = 0.0047), and stomatitis (OR: 4.60, 95% CI: 1.01–21.04, p = 0.0492). Conclusions Among patients with NSCLC, BAP was associated with deteriorating PS during the first cycle of chemotherapy, grade ≥ 3 diarrhea, febrile neutropenia, and stomatitis. Therefore, careful observation is needed for patients with NSCLC who receive Bev in any line of treatment, especially if they develop serious side effects that affect their PS or mucous membrane.

Keywords

Bevacizumab Intestinal perforation NSCLC Prediction markers 

Notes

Acknowledgments

The authors thank all the participants of this study.

Funding

The authors did not receive any funding for this study.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Hoffman PC, Mauer AM, Vokes EE (2002) Lung cancer. Lancet 355:479–485CrossRefGoogle Scholar
  2. 2.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMedGoogle Scholar
  3. 3.
    Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227–1234CrossRefPubMedGoogle Scholar
  4. 4.
    Takeda M, Okamoto I, Yamanaka T, Nakagawa K, Nakanishi Y (2012) Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L). BMC Cancer 12:327CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMedGoogle Scholar
  6. 6.
    Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S, ML18147 Study Investigators (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37CrossRefPubMedGoogle Scholar
  8. 8.
    Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902–2908CrossRefPubMedGoogle Scholar
  9. 9.
    Sliesoraitis S, Tawfik B (2011) Bevacizumab-induced bowel perforation. J Am Osteopath Assoc 111:437–441PubMedGoogle Scholar
  10. 10.
    Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577–582CrossRefPubMedGoogle Scholar
  11. 11.
    Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568CrossRefPubMedGoogle Scholar
  12. 12.
    Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14:277–284CrossRefPubMedGoogle Scholar
  13. 13.
    Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 32:1210–1217CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  15. 15.
    Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T (2013) Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 30:676CrossRefPubMedGoogle Scholar
  16. 16.
    Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A (2013) Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol 71:457–461CrossRefPubMedGoogle Scholar
  17. 17.
    Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U (2009) Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Investig New Drugs 27:184–187CrossRefGoogle Scholar
  18. 18.
    Badgwell B, Feig BW, Ross MI, Mansfield PF, Wen S, Chang GJ (2007) Pneumoperitoneum in the cancer patient. Ann Surg Oncol 14:3141–3147CrossRefPubMedGoogle Scholar
  19. 19.
    Choi YI, Lee SH, Ahn BK, Baek SU, Park SJ, Kim YS, Shin SH (2008) Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 40:33–35CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Heinzerling JH, Huerta S (2006) Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63:334–337CrossRefPubMedGoogle Scholar
  21. 21.
    Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21:303–319CrossRefPubMedGoogle Scholar
  22. 22.
    Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investig New Drugs 26:393–397CrossRefGoogle Scholar
  23. 23.
    Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM (2010) Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118:47–51CrossRefPubMedGoogle Scholar
  24. 24.
    Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25:5150–5152CrossRefPubMedGoogle Scholar
  25. 25.
    Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040CrossRefPubMedGoogle Scholar
  26. 26.
    Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560–H576CrossRefPubMedGoogle Scholar
  27. 27.
    Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298CrossRefPubMedGoogle Scholar
  28. 28.
    Collins D, Ridgway PF, Winter DC, Fennelly D, Evoy D (2009) Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy. Eur J Surg Oncol 35:444–446CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Motohiro Tamiya
    • 1
  • Hidekazu Suzuki
    • 2
  • Takayuki Shiroyama
    • 2
  • Ayako Tanaka
    • 2
  • Naoko Morishita
    • 2
  • Norio Okamoto
    • 2
  • Kenichi Sakai
    • 3
  • Hironori Shigeoka
    • 4
  • Kunimitsu Kawahara
    • 5
  • Tomonori Hirashima
    • 2
  1. 1.Department of Thoracic OncologyOsaka International Cancer InstituteOsakaJapan
  2. 2.Department of Thoracic MalignancyOsaka Habikino Medical CenterHabikinoJapan
  3. 3.Department of SurgeryOsaka Gyoumeikan HospitalOsakaJapan
  4. 4.Department of Emergency & Critical Care MedicineKindai University Faculty of MedicineOsakaJapan
  5. 5.Department of PathologyOsaka Habikino Medical CenterHabikinoJapan

Personalised recommendations